newsfilter
← Latest News
GlobeNewswire·

Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19

The trial in moderate-to-severe patients is Aerpio’s second clinical trial in COVID-19 patients and is funded in part by the U.S. military The military-sponsored trial is complementary to the...